Efficacy News and Research

RSS

Researchers generate patient-specific stem cells

Researchers have isolated the first human embryonic stem cell lines specifically tailored to match the nuclear DNA of patients, both males and females of various ages, suffering from disease or spinal cord injury.

20 May 2005

FDA recommends approval of the investigational anti-HIV drug tipranavir

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee recommended the approval of the investigational anti-HIV drug tipranavir (11-3). Tipranavir is a non-peptidic protease inhibitor that requires boosting with low-dose ritonavir and must be used in combination with other antiretroviral agents.

20 May 2005

Integrated approach to child survival achieving important results

An integrated approach to child survival designed to deliver a package of lifesaving health services for children in hard to reach communities has shown remarkable results, UNICEF Executive Director Ann M. Veneman announced at the World Health Assembly.

18 May 2005

Roche to discontinue the sale and distribution of Fortovase (saquinavir)

Roche announced today that it has decided to discontinue the sale and distribution of Fortovase (saquinavir), as clinical demand for the drug has declined significantly due to the availability of a new formulation of Invirase (saquinavir mesylate), which increasingly has become the preferred formulation of saquinavir.

18 May 2005

More research needed into access to emergency contraception

Experts at The University of Nottingham have called for more research into whether systems for accessing emergency contraception are meeting the needs of younger women and those from poorer backgrounds.

17 May 2005

Antibody combined with cancer drug shows promise against breast tumors

An antibody that targets the blood vessels nourishing tumors significantly reduced breast cancer formation and growth in mice when combined with a current cancer drug, according to researchers at UT Southwestern Medical Center.

16 May 2005

Statin chemoprevention with minimal surveillance could prevent 96 percent of colon cancers

Ulcerative colitis affects about one out of every 2,000 Americans, and after living with the disease for 30 years, nearly 22 percent of those people will develop colon cancer.

16 May 2005

High-risk for melanoma patients no more likely to take proper precautions in the sun

Those considered high-risk for melanoma--the most dangerous form of skin cancer--are no more likely to sunbathe protected than those who are unaware of their risk, according to a new study conducted by McGill University Health Centre (MUHC) researchers.

16 May 2005

Emerging evidence supports early detection, monitoring, and in some cases treatment for children suffering from high blood pressure

One year after recommending that children should be checked for high blood pressure starting at age 3, medical experts reviewed additional supporting evidence for the pediatric blood pressure guidelines at the American Society of Hypertension's Twentieth Annual Meeting (ASH 2005).

16 May 2005

Tarvacin equivalent plus Docetaxel inhibits breast tumor growth by 93%

Peregrine Pharmaceuticals, Inc., today announced that a research article titled "A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice" was published in the May 15 issue of Cancer Research.

16 May 2005

Vaccine candidate to treat nicotine addiction shows promise

Cytos Biotechnology AG has announced that its vaccine candidate CYT002-NicQb to treat nicotine addiction has achieved proof of efficacy.

16 May 2005

Zometa reduces bone loss in patients receiving breast cancer treatment

Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Orlando, Florida, demonstrate that Zometa (zoledronic acid), an intravenous bisphosphonate, was shown to inhibit bone loss in postmenopausal women treated with Femara (letrozole) in the adjuvant breast cancer setting (directly following surgery to prevent cancer recurrence).

16 May 2005

Broader range of treatments for excessive sweating disorder, Mayo Clinic Proceedings says

The often embarrassing, excessive sweating disorder, hyperhidrosis, and its treatment options are gaining greater attention from physicians. This is improving the efficacy of treatment and minimizing its adverse effects, Mayo Clinic authors write in the May issue of Mayo Clinic Proceedings.

11 May 2005

Benitec announces clinical candidate for the treatment of Hepatitis C

Benitec Ltd. announced today that it has identified a highly promising clinical candidate for its RNA interference (RNAi)-based therapeutic against the hepatitis C virus (HCV).

10 May 2005

New treatments for common vaginal infection being studied

Whether a two-week regimen using a stainless steel douching device can eradicate the most common vaginal infection is under study at the Medical College of Georgia.

9 May 2005

Does clinical depression bring about chronic pain? Or does pain lead to depression?

Does clinical depression bring about chronic pain? Or does pain lead to depression? Because these two conditions frequently co-exist--30 to 54 percent of patients with major depressive disorder also suffer persistent physical pain--there has been much speculation about whether one causes the other or whether a common underlying factor provokes both. Results of studies into the precise nature of this relationship, however, have been inconsistent.

5 May 2005

Fear stops some parents vaccinating their children

A new study has found that the majority of parents who choose not to vaccinate their children do so out of fear that the vaccine will cause more harm than the disease it prevents.

4 May 2005

Vaccine developed at Rockefeller University boosts natural killer T cells in patients with cancer

A new vaccine designed at The Rockefeller University boosted a type of fast-responding immune system cell called the natural killer T (NKT) cell in patients with advanced cancer. The study surprised researchers by revealing the ability of these NKT cells to spur other, slower-responding immune cells to go to work.

4 May 2005

New Zealand Ministry of Health to consider Vaxigrip vaccine trial results

Pharmac and the New Zealand Ministry of Health are aware that Sanofi-Pasteur has been running a clinical trial to demonstrate the efficacy of their influenza vaccine, Vaxigrip.

4 May 2005

Boostrix receives FDA approval as treatment for pertussis

GlaxoSmithKline today announced that its booster vaccine, Boostrix received approval from the United States (U.S.) Food and Drug Administration (FDA).

3 May 2005